when is tirzepatide off patent Mounjaro expiration Ozempic's Patent Protection Starts to

Notes: Data are summarized by means with standard deviations

However, recent reports and lawsuits have raised concerns about its potential side effects, some of which can lead to severe and life-threatening conditions

Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026

Together, we can create a plan that aligns with your goals and supports your well-being

The FDA label includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, with contraindication in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2